Vinnof
VC Fund
Brussels, Belgium
Vinnof is a venture capital firm that offers seed capital to innovative, early-stage startups based in Flanders, Belgium.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Vinnof invests in
Stages Vinnof invests in
Countries Vinnof invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Series A
- $9.3M–$11M
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 3 (60%)
- Medical 2 (40%)
- Therapeutics 2 (40%)
- Big Data 1 (20%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Series B 1 (20%)
- Funding Round 1 (20%)
Country
- Belgium 4 (80%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris De Jonghe
Member, Group Management Committee
|
Member, Group Management Committee | Total investments: 3 | Find email | |
Marcel Van Hoven Hand
Chairman
|
Chairman | Total investments: 0 | Find email | |
Christine Claus
Director
|
Director | Total investments: 0 | Find email | |
Clair Ysebaert
Director
|
Director | Total investments: 0 | Find email | |
Greta D'Hondt
Director
|
Director | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Loshai
|
Loshai is a unified Predictive platform that allows that allows data integration, modelling and visualisation using no-code tools . It provides 360 analytics insights on data along with simulations based o what-if scenarios using AI loops. LoshAi's simple UI allows mapping just enough data to answer the business questions at hand. Schema-lessintegration across OT and IT sources. | Seed / Sep 08, 2022 | |
Complix
|
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins. | $13.2M / Series B / Jun 26, 2013 | |
Okapi Sciences
|
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises. | $9.3M / Series A / Nov 03, 2008 | |
Apitope
|
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of productcandidates developed with its proprietary platform technology. | $11M / Series A / Oct 30, 2008 | |
Formac Pharmaceuticals
|
Formac is a spin-off company from the University of Leuven, Belgium (K.U.Leuven), from which it has obtained the exclusive and worldwide rights to develop and commercialise ordered mesoporous silica materials for the delivery of poorly soluble API's. The company was incorporated on 3 October 2007 and is privately owned. The main shareholdersof Formac are K.U.Leuven, Allegro Investment Fund, Hunza Ventures, Gemma Frisius Fonds K.U.Leuven, Vinnof PMV and Life Sciences Research Partners VZW (formerly D. Collen Foundation).Since its incorporation Formac has signed more than 40 feasibility agreements with Tier 1 Pharma companies and SMEs in the field of human and veterinary medicine. To date, Formac is the only company that demonstrated the clinical relevancy of the silica based technology in a clinical setting. | $1.9M / Nov 08, 2007 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Vinnof invest in?
Vinnof invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vinnof's check size?
Vinnof typically joins rounds of $9.3M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vinnof participates in.
How do I contact Vinnof?
Public channels for Vinnof include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vinnof?
The team at Vinnof includes Chris De Jonghe (Member, Group Management Committee), Marcel Van Hoven Hand (Chairman) and Christine Claus (Director), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
